-- FAW Jiefang (SHE:000800) の第1四半期の帰属利益は前年同期の2910万元から242%増の9930万元となった。
同社の1株当たり利益は前年同期の0.0071元から185%増の0.0202元を記録している。
営業収益は前年同期の143億元から31%増の188億元となった。
Related Articles
Commodities
US President Trump Grants Permit for Bridger Pipeline Extension to Canada Border
US President Donald Trump has granted a presidential permit for Bridger Pipeline Expansion, a private Wyoming company and subsidiary of Bridger Pipeline, to construct, connect and operate a pipeline at the border with Canada in Montana for crude oil and refined products, the White House said on Thursday.The pipeline will have a 36-inch diameter and run from the border between the US and Canada to a mainline shutoff valve or pumping station within 2,000 feet of the border, the statement, signed by Trump, said.Conditions applied to the permit include maintaining the facility to a high standard and informing the authorities of any ownership change, among other stipulations.
Mining & Metals
Imperial Oil's Q1 Net Income Falls YoY
Imperial Oil's (IMO.TO) net income dropped year over year in the first quarter, the company said Friday.Imperial Oil booked a net income of C$940 million, or $1.94 per share, falling from $1.29 billion, or $2.52 per share, in the year-ago period.Analysts expected Imperial Oil's earnings at $2.30 per share, according to FactSet.Revenue slipped to $12.45 billion from $12.52 billion while expenses increased to $11.21 billion from $10.83 billion.Upstream production stood at 419,000 gross oil-equivalent barrels per day in the first quarter, rising from 418,000 gross oil-equivalent barrels per day in the year-ago period."Against a backdrop of significant volatility in global commodity markets, we remain committed to our long-standing corporate strategy of maximizing the value of our existing assets while progressing advantaged growth opportunities," Chairman, President and Chief Executive Officer John Whelan said.Imperial Oil declared a dividend of $0.87 per share for the second quarter, unchanged from the first quarter. The dividend is payable July 1 to shareholders of record as of June 4.The company plans to renew its normal course issuer bid in June.
$IMO.TO
Research
Research Alert: Mrna Q1 Beats Estimates Despite Litigation Charge, Pipeline Advances
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Moderna's Q1 2026 revenue tripled to $389M, beating the consensus view by $154M, due to COVID-19 vaccine deliveries under international partnerships. Net loss widened to $(3.40) per share from $(2.52) prior year, though beat consensus by $0.48, primarily due to a $0.9B litigation settlement charge that added $(2.22) to EPS. We view the strong revenue performance and international expansion as positive, with international markets contributing 80% of revenue and completion of the first U.K. partnership shipment. Management maintained the 2026 guidance for up to 10% revenue growth with 50/50 U.S./international split. We believe regulatory milestones including European approval of combination vaccines and pipeline advancement demonstrate execution on its diversification strategy. Key upcoming catalysts include Phase 3 melanoma results, norovirus efficacy data, and the August PDUFA date for seasonal flu vaccine mRNA-1010.
$MRNA